BioCentury | Dec 2, 2020
Distillery Therapeutics

Metalloprotease MYSM1 identified as protective factor in lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Promoting the expression of the metalloprotease MYSM1 could treat systemic lupus erythematous (SLE). MYSM1 mRNA and protein levels were lower in peripheral blood mononuclear cells (PBMCs) from 14 SLE...
BioCentury | Dec 2, 2020
Distillery Therapeutics

Neuraly’s GLP-1R agonist NLY01 for ocular hypertension

DISEASE CATEGORY: Ophthalmic disease INDICATION: Ocular hypertension Penn researchers showed that NLY01 from Neuraly Inc., could treat ocular hypertension. In mice modelling ocular hypertension, the pegylated exenatide reduced retinal ganglion cell death and mRNA levels of...
BioCentury | Nov 30, 2020

Kinaset jumps into severe asthma with $40M to develop inhaled JAK inhibitor

...severe asthma. Marketed biologics for severe asthma, such as anti-IL5RA...
...benralizumab from AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and anti-IL-5...
...joined Kinaset’s board.TARGETSIL-5Interleukin-5IL5RA (CD125) – Interleukin-5 (IL-5) receptor αJAK...
BioCentury | Nov 25, 2020
Product Development

Data Byte: a snapshot of the clinical cutaneous T cell lymphoma pipeline

At least 14 therapies are in the clinic to treat cutaneous T cell lymphoma, a rare cancer of T lymphocytes that primarily affects the skin. The most common subtypes of CTCL are mycosis fungoides and...
BioCentury | Nov 24, 2020
Product Development

Nov. 23 Quick Takes: NIH panel says bamlanivimab should not be considered COVID-19 SOC; plus Eiger, Shionogi-Roche, Kiniksa, Schrödinger, Halozyme-Horizon and Immunicum-DCPrime

NIH panel says bamlanivimab should not be considered standard-of-care for COVID-19NIH’s COVID-19 Treatment Guidelines Panel said there is not enough data to recommend either for or against use of bamlanivimab from Eli Lilly and Co. (NYSE:LLY)...
BioCentury | Nov 19, 2020
Emerging Company Profile

Umoja launches with $53M round to test cell therapy cocktails that expand CAR T cells within patients

Umoja’s assembly of a three-step platform could allow the newly launched start-up to create off-the-shelf cell therapy cocktails that expand CAR T cells within patients to treat solid tumors or hematologic malignancies. Named for a...
BioCentury | Nov 19, 2020
Product Development

Preclinical POC for Codiak’s IL-12 therapy highlight retention benefits of exosomes

Data presented at SITC last week provide preclinical proof of concept for Codiak’s IL-12 therapy and highlight the ability of its exosome-based approach to extend retention in the tumor microenvironment. Codiak BioSciences Inc. (NASDAQ:CDAK) uses...
BioCentury | Nov 14, 2020

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

Among CHMP’s monthly roundup of opinions was an MAA withdrawal for BioMarin’s hemophilia gene therapy linked to EMA concerns about safety and durability — issues that FDA raised in August. EMA said...
BioCentury | Nov 13, 2020
Product Development

A huge sigh of relief, but a long road ahead: AZ’s Pangalos on COVID-19 in a BioCentury audio interview

The interim data from Pfizer and BioNTech showing 90% efficacy this week was at the same time a big step and a baby step for the field, according to Mene Pangalos, who sees a long...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
Items per page:
1 - 10 of 5767